Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Utvärdera effektiviteten och säkerheten för LivPhcD-kapslar i NAFLD-ämnen

29 september 2026 uppdaterad av: TCM Biotech International Corp.

Multicenter, randomiserad, dubbelblind, placebokontrollerad studie för att utvärdera effektiviteten och säkerheten för LivPhcD-kapslar i NAFLD-ämnen

Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.

There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.

LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

110

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Not Required For This Country
      • Taipei, Not Required For This Country, Taiwan, 221
        • National Taiwan University Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

20 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Male or female between 20 and 75 years of age.
  2. Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
  3. Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
  4. CAP ≥ 238 db/m
  5. Fibro scan (transient elastography) F0~F3

Exclusion Criteria:

  1. Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
  2. Type 1 diabetes mellitus.
  3. History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
  4. Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
  5. Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
  6. Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
  7. Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
  8. Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
  9. Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
  10. Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
  11. Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
  12. History of HIV

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placebo

Placebo without active ingredient

Placebo matching LivPhcD cap.

Aktiv komparator: 2 cap.LivPhcD/per day

515mg/LivPhcD cap. 2 cap./per day

2 caps. LivPhcD cap. after meal, once a day

Aktiv komparator: 4 cap.LivPhcD/per day

515mg/LivPhcD cap. 4 cap./per day, BID

4 caps. LivPhcD cap. after meal, BID

Aktiv komparator: 6 cap.LivPhcD/per day

515mg/LivPhcD cap. 6 cap./per day, TID

6 caps. LivPhcD cap. after meal, TID

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Reduction of Liver Fat
Tidsram: 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter)

36 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in liver fat at least 30% reduction
Tidsram: 24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat at least 1 stage reduction
Tidsram: 24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change of liver fat by CAP

24 weeks and 36 weeks
Stable in liver fat
Tidsram: 24 weeks and 36 weeks

Between group difference in the proportion of patients with stable of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fibrosis at least 10% reduction
Tidsram: 24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis at least 1 stage reduction
Tidsram: 24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Stable in liver fibrosis
Tidsram: 24 weeks and 36 weeks

Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change of FIB-4

24 weeks and 36 weeks
Change in ALT
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of ALT

24 weeks and 36 weeks
Change in AST
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AST

24 weeks and 36 weeks
Change in GGT
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of GGT

24 weeks and 36 weeks
Change in AP
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AP

24 weeks and 36 weeks
Change in Bilirubin
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Bilirubin

24 weeks and 36 weeks
Change in Triglyceride
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Triglyceride

24 weeks and 36 weeks
Change in Total Cholesterol
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Total Cholesterol

24 weeks and 36 weeks
Change in HDL-C
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of HDL-C

24 weeks and 36 weeks
Change in LDL-C
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of LDL-C

24 weeks and 36 weeks
Change in TNF-α
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of TNF-α

24 weeks and 36 weeks
Change in C-Reactive Protein
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of C-Reactive Protein

24 weeks and 36 weeks
Change in Albumin
Tidsram: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Albumin

24 weeks and 36 weeks
Occurrence of adverse events and serious adverse events
Tidsram: 24 weeks and 36 weeks

Between group difference in the occurrence of adverse events and serious adverse events.

24 weeks and 36 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 december 2023

Primärt slutförande (Faktisk)

22 december 2025

Avslutad studie (Faktisk)

22 januari 2026

Studieregistreringsdatum

Först inskickad

28 maj 2023

Först inskickad som uppfyllde QC-kriterierna

25 juni 2023

Första postat (Faktisk)

5 juli 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • LivPhcD-001

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera